Hashimoto Kazuhiko, Nishimura Shunji, Ito Tomohiko, Akagi Masao
Department of Orthopedic Surgery, Kindai University Hospital, Osakasayama 589-8511, Japan.
Diagnostics (Basel). 2022 Mar 17;12(3):733. doi: 10.3390/diagnostics12030733.
We aimed to investigate the clinical significance of the expression of NY-ESO-1 and MAGE-A4 in soft tissue sarcoma (STS). Immunostaining for NY-ESO-1, MAGE-A4, and Ki67 was performed using pathological specimens harvested from 10 undifferentiated pleomorphic sarcoma (UPS), nine myxofibrosarcoma (MFS), and three malignant peripheral nerve sheath tumor (MPNST) patients treated at our hospital. We examined the correlation of NY-ESO-1 and MAGE-A4 expression levels with tumor size, histological grade, and SUVmax values. Positive cell rates of various markers were also compared between patients in remission and those who were not in remission. The rates of cases positive for NY-ESO, MAGE-A4, and Ki67 were 50%, 63.6%, and 90.9%, respectively. The average rates of cells positive for NY-ESO, MAGE-A4, and Ki67 in all STS types were 18.2%, 39.4%, and 16.8%, respectively. A positive correlation was observed between rates of cells positive for NY-ESO-1 and MAGE-A4 and between NY-ESO-1 and MAGE-A4 expression levels and clinical features. There was no significant difference in the positive cell rate of NY-ESO-1 or MAGE-A4 between remission and non-remission cases. Our results suggest that NY-ESO-1 and MAGE-A4 expression may be useful for the diagnosis and prognostication of UPS, MFS, and MPNST.
我们旨在研究NY-ESO-1和MAGE-A4在软组织肉瘤（STS）中的表达的临床意义。使用从我院治疗的10例未分化多形性肉瘤（UPS）、9例黏液纤维肉瘤（MFS）和3例恶性外周神经鞘瘤（MPNST）患者获取的病理标本，对NY-ESO-1、MAGE-A4和Ki67进行免疫染色。我们检测了NY-ESO-1和MAGE-A4表达水平与肿瘤大小、组织学分级和SUVmax值之间的相关性。还比较了缓解期患者和未缓解期患者各种标志物的阳性细胞率。NY-ESO、MAGE-A4和Ki67的阳性病例率分别为50%、63.6%和90.9%。所有STS类型中NY-ESO、MAGE-A4和Ki67的平均阳性细胞率分别为18.2%、39.4%和16.8%。观察到NY-ESO-1和MAGE-A4的阳性细胞率之间以及NY-ESO-1和MAGE-A4的表达水平与临床特征之间存在正相关。缓解期和未缓解期病例中NY-ESO-1或MAGE-A4的阳性细胞率无显著差异。我们的结果表明，NY-ESO-1和MAGE-A4的表达可能有助于UPS、MFS和MPNST的诊断和预后评估。
